MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
GOVX - Geovax Labs Inc
$5.40
-0.25(-4.42%)9:00:00 PM 2/25/2021
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Stock news

    02/18/2021GOVX
    Introducing GeoVax Labs (NASDAQ:GOVX), The Stock That Zoomed 111% In The Last Year

    When you buy shares in a company, there is always a risk that the price drops to zero. But when you pick a company that...

    02/11/2021GOVX
    GeoVax Announces Closing of $10.3 Million Bought Deal Offering

    Atlanta, GA, Feb. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the closing of its bought deal offering of 1,644,000 shares of its common stock, which included 204,000 shares sold pursuant to the full exercise of the underwriter’s option to purchase additional shares, at a price to the public of $6.25, les...

    02/9/2021GOVX
    GeoVax Announces Pricing of $9.0 Million Bought Deal Offering

    ATLANTA, GA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that it has entered into an underwriting agreement with Maxim Group LLC under which the underwriter has agreed to purchase, on a firm commitment basis, 1,440,000 shares of common stock of the Company, at a price to the public of $6.25 per share ...

    01/11/2021GOVX
    GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development

    Company Focused on Single-dose Vaccine Against Multiple COVID Strains ATLANTA, GA, Jan. 11, 2021 (GLOBE NEWSWIRE) --  via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in suppor...

    01/5/2021GOVX
    GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

    GeoVax Also Participating in BIO@JPM During “J.P. Morgan Week 2021” ATLANTA, GA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \-- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President and CEO David Dodd will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.The presentation will be available for on-demand listening...

    11/30/2020GOVX
    GeoVax Announces License Agreement With NIH to Support Continued Advancements in Vaccine Development

    Atlanta, GA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVa...